Post Type Archives: News

Glenmark Pharmaceuticals, a global pharmaceutical company focused on innovation and accessibility, announced FDA approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, on March 4th, 2026. According to a company press release, FDA granted the treatment a Competitive Generic Therapy (CGT) designation, meaning the agency considers it to be bioequivalent and therapeutically equivalent […]

FUJIFILM Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today unveils ShunzymeX precision purification technology, which simplifies downstream processing for complex biologics. The technology will be presented this week at the Festival of Biologics conference in San Diego. To streamline purification processes, FUJIFILM Biotechnologies, in collaboration with the University of Edinburgh, developed […]

Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO advancing precision medicines, today announces the appointment of Paul Edwards as Chief People Officer. He will lead Ardena’s global people strategy, strengthening organizational capability and supporting the company’s continued international growth. Paul brings over 30 years of Human Resources leadership experience in complex, science-driven organizations. He joins […]

New genetically engineered CHO host cell line strengthens manufacturing efficiency Delivers up to two-fold higher protein expression, three-fold increase in productivity Host provides robust, long-term genetic and phenotypic stability, supporting reliable performance and providing greater confidence through scale-up and regulatory milestones Sartorius is addressing the increasing demand for faster and more efficient cell line development […]

Esperion Therapeutics, a commercial-stage biopharmaceutical company advancing cardiometabolic and rare disease therapies, announced plans to acquire Corstasis Therapeutics, a company advancing treatments for heart failure, liver disease, and kidney disease, on March 3rd, 2026. Corstasis’ portfolio includes the recently FDA-approved Enbumsyt (bumetanide nasal spray), a nasal spray diuretic approved by FDA in September 2025 as […]

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Blackstone Life Sciences (BXLS), a private life sciences investment company, announced a $400 million strategic funding agreement on March 3rd, 2026. Spread across the next four years, the funding agreement will support the continued clinical development of duvakitug, a monoclonal antibody Teva is developing as […]

Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic medicines in the United States, announced the launch of Pomalidomide Capsules, a generic version of Pomalyst® by Celgene (now Bristol Myers Squibb), within the oncology therapeutic category. The product was developed in collaboration with NATCO Pharma Limited of India. With this launch, […]

Novo Nordisk today announced an investment of 432 million euro (approx. DKK 3.2 billion) in its facility in Monksland, Athlone, Ireland. This tabletting facility will provide significant additional manufacturing capacity for current and future Novo Nordisk GLP-1 treatments. The investment is a major strategic milestone for the company, which further reinforces Novo Nordisk’s long-term commitment […]

Argo Biopharma, a clinical-stage biotechnology company advancing next-generation siRNA therapies, announced the appointment of Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer on March 2nd, 2026. Dr. Wang joins Argo from Barclays, where she served as Managing Director, senior research analyst of Small and Mid-Cap Biotechnology. According to a company press release, […]

WuXi XDC, a CRDMO specializing in antibody-drug conjugates (ADCs) and other bioconjugates, and Earendil Labs, a biotech company advancing biologics for the treatment of autoimmune diseases, cancer, and other conditions with unmet medical needs, announced a strategic collaboration on February 27th, 2026. The deal grants Earendil an exclusive global license to the WuXiTecan-2 payload-linker technology […]